https://www.selleckchem.com/pr....oducts/durvalumab.ht
The primary outcomes include mortality rate, morbidity, interleukin-6, tumor necrosis factor-alpha, clinical improvement, symptoms improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc. Finally, we will conducted a meta-analysis through Review Manager Software version 5.3. The results will be published in peer-reviewed journals and presented at a relevant conference. This study will explore the effectiveness and safety of DPP-4 inhibitors in the treatme
Like
Comment
Share
